Commentary: Aromatase inhibitors and musculoskeletal adverse events : The Lancet Oncology

Aromatase inhibitors and musculoskeletal adverse events : The Lancet Oncology

".........Because symptom collection is so variable between trials, researchers could look for correlations between changes in patient-reported quality of life and breast-cancer outcomes. Nevertheless, if clinical research confirms a link between emergent symptoms or changes in quality of life and breast-cancer outcomes, further pharmacogenomic and pharmacogenetic studies could help to elucidate the mechanisms. Although confirmation of the association between emergent symptoms with aromatase inhibitors and risk of breast-cancer recurrence would help to guide clinical advice, based on current evidence clinicians should not use the onset of musculoskeletal symptoms to infer which patient will, or will not, benefit from adjuvant treatment with aromatase inhibitors."

abstract: Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early brea

video: SABCS 2010: Aromatase Inhibitors May Increase Risk for Cardio Vascular Disease with Dr. Eitan Amir, MD - Princess Margaret Hospital

FDA Alert: Aromatase Inhibitors in Products Marketed as Dietary Supplements: Recall

Mayo Collaboration Finds Source of Breast Drug Side Effect - Drugs.com MedNews (aromatase inhibitors/arthritis/bone pain)

Mayo Collaboration Finds Source of Breast Drug Side Effect

Pharmacogenomic discovery allows for improved cancer therapy

ROCHESTER, Minn. — Mayo Clinic researchers and their international colleagues have discovered genetic variants that lead to severe arthritis for a subset of women when taking aromatase inhibitors to treat their breast cancer. This serious side effect is so painful that many women halt their lifesaving medication. The findings appear today in the online issue of Journal of Clinical Oncology.


Read more: http://www.drugs.com/clinical_trials/mayo-collaboration-finds-source-breast-10214.html#ixzz10seG0Pnb

Author's Reply to Correspondence: Endocrine Effects of Aromatase Inhibitors Journal of Clinical Oncology

" It is somehow astonishing that after approximately 15 years from the first clinical article on anastrozole, exemestane, and letrozole, we still have insufficient or weak knowledge of some of the consequences of their long-term use."